Key Takeaway: CAMP4 has secured regulatory clearance in two jurisdictions to initiate its first-in-human Phase 1/2 clinical trial of CMP-002, targeting patients with SYNGAP-1 related disorder. The trial is expected to begin in the fourth quarter of 2026. Additionally, the company successfully raised $50.1 million from a fully subscribed second closing of private funding.
Market Sentiment Analysis
POSITIVE FACTORS
Secured regulatory clearance for Phase 1/2 trial.
Anticipated trial initiation in Q4 2026.
Received $50.1 million from private funding.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~24 mo
Minimal dilution risk
Lead asset
CMP-CPS-001
Phase 1 · Healthy Volunteers
Full Press Release Details
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. Received $50.1 million from fully subscribed second closing of private
Frequently Asked Questions
What is the CMP-002 clinical trial about?
The CMP-002 clinical trial targets patients with SYNGAP-1 related disorder.
When is the CMP-002 trial expected to start?
The trial initiation is anticipated in the fourth quarter of 2026.
How much funding did CAMP4 secure?
CAMP4 received $50.1 million from a fully subscribed second closing of private funding.
In how many jurisdictions was regulatory clearance secured?
Regulatory clearance was secured in two jurisdictions.